Nedosiran
Sponsors
Dicerna Pharmaceuticals, Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Conditions
Primary HyperoxaluriaPrimary Hyperoxaluria Type 1Primary Hyperoxaluria Type 1 (PH1)Primary Hyperoxaluria Type 1, 2 & 3.
hyperoxaluriaPrimary Hyperoxaluria Type 2Primary Hyperoxaluria Type 3
Phase 2
Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
CompletedNCT05001269
Start: 2022-02-22End: 2025-02-05Updated: 2026-04-16
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients from Birth to 5 Years of Age with Primary Hyperoxaluria and Relatively Intact Renal Function
Active, not recruitingLBCTR2021104866
Start: 2021-12-06Target: 5Updated: 2026-02-02